This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Apr 3;375(9721):1140-2.

doi: 10.1016/S0140-6736(10)60098-0. Epub 2010 Feb 18.

Composite renal endpoints: was ACCOMPLISH accomplished?

Hiddo Lambers Heerspink¹, Dick de Zeeuw

Affiliations

PMID: 20170949
DOI: 10.1016/S0140-6736(10)60098-0

Comment

Composite renal endpoints: was ACCOMPLISH accomplished?

Hiddo Lambers Heerspink et al. Lancet. 2010.

. 2010 Apr 3;375(9721):1140-2.

doi: 10.1016/S0140-6736(10)60098-0. Epub 2010 Feb 18.

Authors

Hiddo Lambers Heerspink¹, Dick de Zeeuw

Affiliation

¹ Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, Netherlands.

PMID: 20170949
DOI: 10.1016/S0140-6736(10)60098-0

No abstract available

PubMed Disclaimer

Comment on

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Bakris GL, et al. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18. Lancet. 2010. PMID: 20170948 Clinical Trial.

Similar articles

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Bakris GL, et al. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18. Lancet. 2010. PMID: 20170948 Clinical Trial.
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Davis BR, Whelton PK; ALLHAT Collaborative Research Group. Davis BR, et al. N Engl J Med. 2009 Mar 12;360(11):1148-9; author reply 1149-50. N Engl J Med. 2009. PMID: 19283889 No abstract available.
Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
Mourad JJ, Le Jeune S, Pirollo A, Mourad C, Gaudouen Y, Lopez-Sublet M. Mourad JJ, et al. Curr Med Res Opin. 2010 Sep;26(9):2263-76. doi: 10.1185/03007995.2010.510925. Curr Med Res Opin. 2010. PMID: 20690889 Review.
Hypertension: an ACCOMPLISHED regimen for hypertension.
Turnbull F. Turnbull F. Nat Rev Nephrol. 2009 Apr;5(4):183-4. doi: 10.1038/nrneph.2009.25. Nat Rev Nephrol. 2009. PMID: 19322179 No abstract available.
[Treatment for the elderly hypertensive patient with renal insufficiency].
Kobayashi K, Kanno Y, Suzuki H. Kobayashi K, et al. Nihon Rinsho. 2005 Jun;63(6):1047-51. Nihon Rinsho. 2005. PMID: 15948389 Review. Japanese.

See all similar articles

Cited by

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Davis TM, et al. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. Diabetologia. 2011. PMID: 21052978 Clinical Trial.
Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus.
[No authors listed] [No authors listed] Kidney Int Suppl (2011). 2012 Dec;2(5):357-362. doi: 10.1038/kisup.2012.53. Kidney Int Suppl (2011). 2012. PMID: 25018962 Free PMC article. No abstract available.
Development of hyperkalemia following treatment with dapagliflozin (DAPA) in a patient with type 2 diabetes after bilateral adrenalectomy.
Miyaoka D, Tsuda A, Hayashi N, Toi N, Yamasaki A, Nagata Y, Nakatani S, Kurajoh M, Yamada S, Morioka T, Imanishi Y, Emoto M, Inaba M. Miyaoka D, et al. CEN Case Rep. 2018 May;7(1):29-33. doi: 10.1007/s13730-017-0286-x. Epub 2017 Nov 13. CEN Case Rep. 2018. PMID: 29134558 Free PMC article.
The kidney in type 2 diabetes therapy.
Heerspink HJ, de Zeeuw D. Heerspink HJ, et al. Rev Diabet Stud. 2011 Fall;8(3):392-402. doi: 10.1900/RDS.2011.8.392. Epub 2011 Nov 10. Rev Diabet Stud. 2011. PMID: 22262076 Free PMC article. Review.
Optimal therapy in hypertensive subjects with diabetes mellitus.
Reboldi G, Gentile G, Angeli F, Verdecchia P. Reboldi G, et al. Curr Atheroscler Rep. 2011 Apr;13(2):176-85. doi: 10.1007/s11883-011-0160-9. Curr Atheroscler Rep. 2011. PMID: 21234720 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information